Seattle-based Cyrus Biotechnology says it’ll collaborate with the Broad Institute of MIT and Harvard on methods to optimize CRISPR gene-editing strategies to be used in creating novel human therapeutics.
- CRISPR has revolutionized genetics by making it simpler to switch the DNA coding within the genome, however extra must be executed to handle security issues for human purposes. Cyrus Biotech and the Broad Institute will work on methods to cut back the potential for the physique to mount an immune response towards CRISPR-based therapies.
- MIT biochemist Feng Zhang, one of many pioneers within the improvement of CRISPR, would be the principal investigator for the trouble on the Broad Institute. The outcomes of the collaboration can be printed in peer-reviewed journals and made freely accessible to the educational and non-profit scientific neighborhood.
- Privately held Cyrus Biotech presents software program and partnerships to speed up the invention of engineered proteins, primarily for therapeutic purposes. Its software program instruments are derived from the Rosetta protein-modeling platform, which was developed on the College of Washington.